ZAI LAB LIMITED Increase (Decrease) in Other Noncurrent Assets
ZAI LAB LIMITED (ZLAB) reported Increase (Decrease) in Other Noncurrent Assets of $418.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-06
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was $340.00K, a 74.81% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $78.00K.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was $973.00K, a 114.79% increase year-over-year.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was -$548.00K, a 172.39% decline year-over-year.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for fiscal 2025 was $374.00K, a 74.06% decline from fiscal 2024.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for fiscal 2024 was $1.44M.
- ZAI LAB LIMITED increase (decrease) in other noncurrent assets for fiscal 2023 was -$187.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $340.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $418.00K 10-Q · filed 2026-08-06 | $1.39M derived: sum of 3 quarters · filed 2026-08-06 | $843.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $78.00K 10-Q · filed 2026-05-07 | $1.05M derived: sum of 2 quarters · filed 2026-05-07 | $503.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $973.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $425.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.77M derived: sum of 3 quarters · filed 2026-08-06 | $374.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$548.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $802.00K derived: sum of 2 quarters · filed 2026-08-06 | -$599.00K 10-Q · filed 2025-11-06 | -$146.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$51.00K 10-Q · filed 2026-08-06 | $402.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.40M 10-Q · filed 2026-05-07 | -$948.00K derived: sum of 2 quarters · filed 2026-05-07 | -$191.00K derived: sum of 3 quarters · filed 2026-05-07 | -$230.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $453.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.21M derived: sum of 2 quarters · filed 2026-02-26 | $1.17M derived: sum of 3 quarters · filed 2026-02-26 | $1.44M 10-K · filed 2026-02-26 |
| 2024-09-30 | $757.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $718.00K derived: sum of 2 quarters · filed 2025-11-06 | $989.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $232.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $271.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$187.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |